Business
Resolve M Therapeutics exits from stealth
Resolve M Therapeutics, Inc., the biotech aiming to build the world's first comprehensive pro-resolution platform for target ID, validation and drug discovery for the treatment of inflammatory diseases, has announced its exit from stealth. Resolve M was created through a strategic collaboration between Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc., and General Inception, the global biotech company igniter, and reflects a bold com
About this update from Johnson & Johnson
[{"type":"text","content":"Unique platform designed to engage pro-resolution responses to restore immune homeostasis in inflammatory disorders without broad immuno-suppression.","length":154,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., Jan. 22, 2026 /PRNewswire/ -- Resolve M Therapeutics, Inc., the biotech aiming to build the world's first comprehensive pro-resolution platform for target ID, validation and drug discovery for the treatment of inflammatory diseases, has announced its exit from stealth. Resolve M was created through a strategic collaboration between Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc., and General Inception, the global biotech company igniter, and reflects a bold commitment to early-stage biotech innovation.","length":607,"tagName":"p"},{"type":"text","content":"Leveraging differentiated insights and capabilities from Professor Nir Hacohen's lab at the Broad Institute, Resolve M's groundbreaking platform aims to harness the pro-resolving potential of the MS1 (myeloid state 1) cell to restore homeostasis in patients with chronic inflammatory and autoimmune disorders, without completely shutting down the immune system. This approach offers a potentially safer and more effective therapeutic option than is currently available. Pro-resolving mechanisms restore tissues to homeostasis after an infection or injury during the resolution phase of inflammation.","length":607,"tagName":"p"},{"type":"text","content":"Professor Nir Hacohen, core member of the Broad Institute and professor of medicine at Harvard Medical School said: "Our findings of a defined myeloid cell state with suppressive functions provides a platform for induction, or modulation, of immune cells and their functions for therapeutic purposes in diverse inflammatory conditions."","length":346,"tagName":"p"},{"type":"text","content":"Engaging the pro-resolving response has long been an area of active investigation because of its transformative potential. However, prior efforts in this field have focused primarily on resolving lipid mediators, which have not met expectations in the clinic. Johnson & Johnson Innovation - JJDC Inc. and General Inception have recognized the potential of Professor Hacohen's platform to drive pro-resolving cells in vivo an...